Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

SCRI Development Innovations

Status and phase

Completed

Phase 2

Conditions

Lung Cancer

Treatments

Drug: Topotecan

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00193388

104864664

SCRI LUN 66

Details and patient eligibility

About

In this phase II trial, we will evaluate the weekly schedule of topotecan in the second-line treatment of patients with small cell lung cancer

Full description

Upon determination of eligibility, all patients will be receive:

Topotecan

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

To be included in this study, you must meet the following criteria:

Small Cell Lung cancer
Progression after one previous regimen
Measurable or evaluable disease
Able to perform activities of daily living with assistance
Adequate bone marrow, liver and kidney function
No more than three previous courses of radiation therapy
Accessible for treatment and follow up
Must give written informed consent prior to study entry

Exclusion criteria

You cannot participate in this study if any of the following apply to you:

Central nervous system involvement
Serious or active infection
Serious underlying medical condition
Other active neoplasms

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.